- Home
- PPBI vs LIVN Comparison
PPBI vs LIVN Comparison
Compare PPBI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- LIVN
- Stock Information
- Founded
- PPBI 1983
- LIVN 1987
- Country
- PPBI United States
- LIVN United Kingdom
- Employees
- PPBI N/A
- LIVN N/A
- Industry
- PPBI Major Banks
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PPBI Finance
- LIVN Health Care
- Exchange
- PPBI Nasdaq
- LIVN Nasdaq
- Market Cap
- PPBI 2.4B
- LIVN 2.8B
- IPO Year
- PPBI 1997
- LIVN 1993
- Fundamental
- Price
- PPBI $24.58
- LIVN $48.30
- Analyst Decision
- PPBI Buy
- LIVN Buy
- Analyst Count
- PPBI 6
- LIVN 7
- Target Price
- PPBI $26.50
- LIVN $67.14
- AVG Volume (30 Days)
- PPBI 482.8K
- LIVN 483.1K
- Earning Date
- PPBI 01-23-2025
- LIVN 02-19-2025
- Dividend Yield
- PPBI 5.37%
- LIVN N/A
- EPS Growth
- PPBI N/A
- LIVN 759.09
- EPS
- PPBI N/A
- LIVN 0.43
- Revenue
- PPBI $379,785,000.00
- LIVN $1,241,739,000.00
- Revenue This Year
- PPBI N/A
- LIVN $10.10
- Revenue Next Year
- PPBI N/A
- LIVN $5.43
- P/E Ratio
- PPBI N/A
- LIVN $112.77
- Revenue Growth
- PPBI N/A
- LIVN 11.04
- 52 Week Low
- PPBI $20.52
- LIVN $43.15
- 52 Week High
- PPBI $30.28
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- PPBI 45.26
- LIVN 50.54
- Support Level
- PPBI $23.93
- LIVN $47.23
- Resistance Level
- PPBI $24.99
- LIVN $48.73
- Average True Range (ATR)
- PPBI 0.67
- LIVN 1.13
- MACD
- PPBI 0.07
- LIVN 0.29
- Stochastic Oscillator
- PPBI 66.33
- LIVN 85.90
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.